Clinical Frailty Score vs Hospital Frailty Risk Score for predicting mortality and other adverse outcome in hospitalised patients with COVID‐19: Spanish case series
Authors:
- Jose-Manuel Ramos-RinconJose-Manuel Ramos-Rincon
- Oscar Moreno-PerezOMOscar Moreno-Perez
- Hector Pinargote-CelorioHector Pinargote-Celorio
- Jose-Manuel Leon-RamirezJose-Manuel Leon-Ramirez
- Mariano AndresMariano Andres
- Vicente BoixVicente Boix
- Joan GilJGJoan Gil
- Rosario Sanchez-MartinezRSRosario Sanchez-Martinez
- Esperanza MerinoEMEsperanza Merino
Open Access
- 16 July 2021
- journal article
- research article
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 75 (10) , e14599
Abstract
Objectives Frailty can be used as a predictor of adverse outcomes in people with coronavirus disease 2019 (COVID-19). The aim of the study was to analyse the prognostic value of two different frailty scores in patients hospitalised for COVID-19. Material and Methods This retrospective cohort study included adult (≥18 years) inpatients with COVID-19 and took place from 3 March to 2 May 2020. Patients were categorised by Clinical Frailty Score (CFS) and Hospital Frailty Risk Score (HFRS). The primary outcome was in-hospital mortality, and secondary outcomes were tocilizumab treatment, length of hospital stay, admission in intensive care unit (ICU) and need for invasive mechanical ventilation. Results were analysed by multivariable logistic regression and expressed as odds ratios (ORs), adjusting for age, sex, kidney function and comorbidity. Results Of the 290 included patients, 54 were frail according to the CFS (≥5 points; prevalence 18.6%, 95% confidence interval [CI]: 14.4-23.7) vs 65 by HFRS (≥5 points; prevalence: 22.4%, 95% CI 17.8-27.7). Prevalence of frailty increased with age according to both measures: 50-64 years, CFS 1.9% vs HFRS 12.3%; 65-79 years, CFS 31.5% vs HFRS 40.0%; and ≥80 years, CFS 66.7% vs HFRS 40.0% (P < .001). CFS-defined frailty was independently associated with risk of death (OR 3.67, 95% CI 1.49-9.04) and less treatment with tocilizumab (OR 0.28, 95% CI 0.08-0.93). HFRS-defined frailty was independently associated with length of hospital stay over 10 days (OR 2.89, 95% CI 1.53-5.44), ICU admission (OR 4.18, 95% CI 1.84-9.52) and invasive mechanical ventilation (OR 5.93, 95% CI 2.33-15.10). Conclusion In the spring 2020 wave of the COVID-19 pandemic in Spain, CFS-defined frailty was an independent predictor for death, while frailty as measured by the HFRS was associated with length of hospital stay over 10 days, ICU admission and use of invasive mechanical ventilation.Keywords
This publication has 33 references indexed in Scilit:
- Frailty and COVID-19: A Systematic Scoping ReviewJournal of Clinical Medicine, 2020
- Frailty index predicts poor outcome in COVID-19 patientsIntensive Care Medicine, 2020
- Decision-Making in COVID-19 and FrailtyGeriatrics, 2020
- Age is just a number – and so is frailty: Strategies to inform resource allocation during the COVID-19 pandemicCanadian Journal of Emergency Medicine, 2020
- Association of Frailty With 30-Day Outcomes for Acute Myocardial Infarction, Heart Failure, and Pneumonia Among Elderly AdultsJAMA Cardiology, 2019
- Frailty and related outcomes in patients undergoing transcatheter valve therapies in a nationwide cohortEuropean Heart Journal, 2019
- Frailty predicts mortality in all emergency surgical admissions regardless of age. An observational studyAge and Ageing, 2019
- Frailty Consensus: A Call to ActionJournal of the American Medical Directors Association, 2013
- Frailty in Relation to the Accumulation of DeficitsThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2007
- Frailty in Older Adults: Evidence for a PhenotypeThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2001